Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

Media reports touting ketamine as a miracle drug for severe depression have contributed to confusion about the differences between ketamine and its esketamine, experts said.

In 2023, esketamine showed superiority to quetiapine when it exhibited a 54% increased likelihood of patients reaching remission for treatment-resistant depression (TRD) at 8 weeks. 2 TRD affects ...

Esketamine plus SNRI cohort showed better survival probability than esketamine pls SSRI group. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

Esketamine nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitor (SNRI), is the only treatment ...

After screening and randomization, 95 patients received 84 mg esketamine, 86 patients received 56 mg esketamine, and 197 received placebo. About 61% were female, 86.8% were white, and 65.6% were ...

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

BARCELONA — Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca), an atypical antipsychotic, for treatment-resistant depression (TRD ...

Compared with saline, administration of low-dose esketamine significantly reduced the composite outcome of desaturation and hypotension (8.2% vs. 21%; risk difference = –12.8 percentage points ...

Veterans interested in the Esketamine treatment can ask for a referral from their mental health provider. For additional information, call: 407-631-4762.